Overview of Ibunastizol

Quick Facts

Property	Description
Active ingredient	Ibuprofen, Pseudoephedrine Hydrochloride
Form	Oral Solid (Capsules, Tablets, Caplets)
Pharmacological class	Combination Analgesic and Sympathomimetic Decongestant
General purpose	Symptomatic relief of pain, fever, and nasal congestion
Origin	Synthetic chemical compounds

What is Ibunastizol and How is it Classified?

Ibunastizol is defined as a fixed-dose combination drug intended for systemic administration that belongs to the combined analgesic and sympathomimetic decongestant pharmacological class. This preparation is classified as a combination product because it unites two distinct, synthetic active components into a single dosage unit. The drug's classification reflects its dual function, a strategy clinically recognized for efficiently managing multiple symptoms of the common cold simultaneously. Ibunastizol is often noted for its capsule or caplet formulations, distributed by manufacturers like Laboratorios Bagó in various markets.

The Dual Composition of Ibunastizol

The medication's effectiveness stems from its two primary active ingredients: Ibuprofen and Pseudoephedrine Hydrochloride. Ibuprofen is the component classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), which acts as an analgesic and antipyretic. The established efficacy of NSAIDs in providing pain and fever relief is well-documented in medical literature. Pseudoephedrine Hydrochloride is the second component, classified as a sympathomimetic amine that primarily functions as a nasal decongestant. The final product is manufactured in oral solid dosage forms, typically for absorption via the oral route.

Ibunastizol’s General Therapeutic Purpose

The general therapeutic purpose of Ibunastizol is to provide comprehensive symptomatic relief by targeting multiple areas of discomfort simultaneously, such as when experiencing a cold or flu. The formulation leverages the ability of Ibuprofen to interrupt pain and inflammatory signals alongside the effect of Pseudoephedrine to constrict blood vessels in the nasal passages. This integrated approach is particularly beneficial for users experiencing concurrent discomforts such as headache, minor body aches, elevated fever, and bothersome sinus pressure resulting from nasal blockage.

Regulatory References

What side effects are possible with Ibunastizol?

Possible Side Effects and Safety Information

The safety profile for Ibunastizol is derived exclusively from regulatory documents and post-marketing surveillance reports submitted to health authorities, such as the Japan Pharmaceuticals and Medical Devices Agency (PMDA).

Adverse Reactions by Frequency and System Organ Class

Official regulatory sources classify possible side effects based on how frequently they occurred in clinical trials and post-approval use. These reactions are typically categorized by the affected System Organ Class (SOC).

Frequency Classification	Examples of Affected System Organ Class (SOC)
Common (may affect up to 1 in 10 people)	Gastrointestinal disorders (e.g., nausea, abdominal discomfort), Nervous system disorders (e.g., headache, somnolence)
Uncommon (may affect up to 1 in 100 people)	Skin and subcutaneous tissue disorders (e.g., rash, pruritus), General disorders (e.g., fatigue)
Rare (may affect up to 1 in 1,000 people)	Hepatobiliary disorders (e.g., elevated liver enzymes), Immune system disorders (e.g., hypersensitivity reactions)

Serious Adverse Reactions

Specific serious adverse reactions, while rare, have been officially documented and require attention within the regulatory framework. These reactions often relate to severe systemic responses, such as anaphylaxis or severe skin reactions (e.g., Stevens-Johnson syndrome), which represent clinically significant safety concerns.

Safety-Related Restrictions

Regulatory documentation highlights certain populations or conditions where caution or restricted use is advised, often due to an increased risk of adverse events. For Ibunastizol, these safety limitations often involve patients with pre-existing hepatic impairment due to the drug's metabolism, and specific consideration is given to its use in elderly patients, where monitoring for central nervous system effects may be recommended by the regulatory label. No use is recommended for pediatric patients due to a lack of sufficient safety data in official documents.

Overdose and Emergency Response

Overdose involving Ibunastizol (a combination of Ibuprofen and Pseudoephedrine) results in manifestations derived from both active components. Immediate medical attention is required for any suspected overdose.

Documented Clinical Manifestations

Overdose presentations involve both gastrointestinal and central nervous system (CNS) effects. Documented manifestations may include:

System Affected	Overdose Presentations (as stated in label)
Gastrointestinal	Nausea, vomiting, stomach pain, diarrhea, and heartburn.
Central Nervous System	Drowsiness, confusion, agitation, restlessness, severe headache, and tinnitus.
Cardiovascular	Hypertension, hypotension, fast, pounding, or irregular heartbeat.

Severe Outcomes and Emergency Action

The official profile documents the risk of serious or fatal outcomes, including gastrointestinal bleeding, ulceration, or perforation, as well as convulsions (seizures) or cardiovascular collapse. Regulators mandate that a Poison Control Center or emergency services must be contacted immediately. Call 911 or your local emergency services if the individual has collapsed, is seizing, or has trouble breathing.

Management and Population Risk

No specific antidote is known for the Ibuprofen component; therefore, management is symptomatic and supportive, requiring hospital monitoring of vital signs. The official labeling notes that older adults have an increased risk for serious gastrointestinal and renal adverse effects. Pediatric patients ingesting high doses of the Ibuprofen component are also noted for an increased risk of severe effects.

Therapeutic Uses of Ibunastizol

Ibunastizol is an oral combination medication designed for symptomatic relief in clinical situations where patients experience multiple, concurrent manifestations of illness. The focus is on providing supportive therapeutic assistance across key symptom domains commonly associated with acute conditions. Its therapeutic scope is aligned with established indications for its active components, which include addressing symptoms associated with the common cold or flu, such as headache, fever, sinus pressure, nasal congestion, and minor body aches and pains. This dual approach helps manage symptoms related to systemic imbalance alongside nasal obstruction in acute episodes.

This combination is commonly used when symptoms intensify and supportive relief is needed, providing temporary assistance to cope more steadily with difficult manifestations. The product is indicated for these symptoms.

“This medication helps address symptom clusters that may become intense or disruptive, offering supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Dual Symptom Domains

Symptom Domain	Key Benefit
Systemic (Pain & Fever)	Contributes to improved comfort by easing body aches and reducing fever.
Nasal & Sinus (Obstruction)	Supports easier breathing and relief from sinus pressure.

Regulatory References

Label: IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE tablet, sugar coated

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents define the eligible user population for Ibunastizol (Ibuprofen/Pseudoephedrine) as adults and adolescents 12 years of age and older. Use in children under 12 years of age is strictly contraindicated as safety is not established for this age group.

Absolute Contraindications (Must Not Use):

Patients with severe heart failure, severe renal failure, or severe hepatic insufficiency.
Individuals with uncontrolled severe hypertension, coronary heart disease, or those near Coronary Artery Bypass Graft (CABG) surgery.
Patients with a history of active or recurrent peptic ulcers or gastrointestinal bleeding related to NSAID use.
Individuals who have taken a Monoamine Oxidase Inhibitor (MAOI) within the past 14 days.
Patients with a known allergy to aspirin or any other NSAID.
Women in the third trimester of pregnancy (last 3 months).

Restricted or Conditional Use:

Use is generally not recommended for breastfeeding mothers or for pregnant women in the first and second trimesters. Older adults (geriatric patients) should use this medicine with caution due to the heightened risk of serious gastrointestinal events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ibunastizol is a fixed-dose combination drug containing Ibuprofen and Pseudoephedrine Hydrochloride. The official regulatory profile outlines specific drug–drug and drug–substance interactions based on the activity of these two components.

Official Regulatory Restrictions and Outcomes

Interaction Type	Interacting Agent(s)	Official Regulatory Outcome
Contraindicated Combinations	Monoamine Oxidase Inhibitors (MAOIs), Other NSAIDs	Risk of hypertensive crisis (MAOIs) or severe gastrointestinal bleeding (NSAIDs). Co-administration is prohibited.
Pharmacokinetic Interactions	Lithium, Methotrexate, Digoxin	Ibuprofen may reduce the renal clearance of these agents, potentially leading to increased plasma concentrations.
Pharmacodynamic Interactions	Anti-hypertensives, Other Sympathomimetic Agents	Pseudoephedrine may reduce the blood-pressure-lowering effect of anti-hypertensives and cause additive pressor effects with other sympathomimetics.
Timing-Based Rules	Low-dose Aspirin (for cardioprotection)	Administration of Ibuprofen must be separated from low-dose Aspirin by a specific time frame (e.g., eight hours before or 30 minutes after) to avoid interfering with the antiplatelet effect.
Substance Interaction	Alcohol (Ethanol)	Concurrent use of Ibuprofen with alcohol significantly increases the risk of serious gastrointestinal adverse events.

Official regulatory documents emphasize that the co-administration of certain medicines and substances with Ibunastizol requires strict adherence to documented constraints. The profile mandates absolute prohibitions for certain combinations and highlights the need for vigilance when combining the Ibuprofen component with agents that affect renal clearance or coagulation.

Mechanism of Action

How Ibunastizol Works

The mechanism of Ibunastizol involves two distinct, complementary mechanistic domains that affect inflammatory signaling pathways and local vascular dynamics. The Ibuprofen component functions as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes (specifically COX-1 and COX-2). This molecular interaction reduces the synthesis of prostaglandins ( PGE2), which are lipid mediators that contribute to nociceptor sensitization and the elevation of the hypothalamic temperature set-point. The resulting cascade decreases the levels of these mediators, which reduces nociceptor sensitization and lowers the hypothalamic temperature set-point.

The Pseudoephedrine component is a sympathomimetic amine that primarily targets the alpha-Adrenergic Receptors on blood vessels in the upper respiratory tract. By acting as a direct and indirect agonist, this component causes the vasoconstriction of arterioles and capillaries in the nasal and sinus mucosa. This mechanism causes vasoconstriction, which reduces the localized blood flow and capillary hydrostatic pressure within the vascular pathways. Ibuprofen modulates the biochemical signaling of inflammation, while Pseudoephedrine affects the vascular dynamics that govern tissue volume.

Dosage and Administration Information

How to Use Ibunastizol

Ibunastizol (Ibuprofen/Pseudoephedrine Hydrochloride) is a fixed-dose combination medication with oral administration as the only approved route, generally supplied as a tablet, caplet, or capsule. The medication is designed for systemic use, and its administration is structured by guidelines defining specific dose limits and timing.

Official Administration Guidelines

Administration of Ibunastizol follows an as-needed schedule for adults and children 12 years of age and older. The primary instruction is to always use the smallest effective dose and not to exceed the established daily maximum.

Usage Parameter	Instruction
Standard Single Dose	One unit (200 mg Ibuprofen / 30 mg Pseudoephedrine)
Adjusted Single Dose	Two units, only if symptoms are unresponsive to one unit
Maximum Daily Dose	Six units (1200 mg Ibuprofen / 180 mg Pseudoephedrine) in any 24-hour period
Frequency	Every 4 to 6 hours

Context of Intake and Restrictions

To aid with potential gastric discomfort, the medication may be taken with food or milk. The labeled usage is strictly limited to short-term administration; usage beyond the directed time should be avoided. The medication is explicitly prohibited for use in children under 12 years of age. Furthermore, clinical information advises against using the preparation in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2). Adhering to these principles ensures the consistent, label-aligned use of the product.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research has explored whether the quality of life might be affected by the use of this substance. Findings from multiple small-scale trials and observational studies were collected for review. The evidence remains limited regarding the long-term association with symptom change.

Dosing: The research reviewed focused on specific dosage levels (100mg to 200mg) used in adult populations.
Safety: Research reviewed included assessments of patient tolerability within specific populations, such as those with mild hepatic impairment.

Studies on Symptom Association

Specific research looked at whether pain and inflammation were associated with treatment.

Short-Term Studies

Early-stage investigations, including several non-randomized, open-label trials, examined the use over a period of 4 to 8 weeks.

Symptom Change: Research looked at the timeframe for changes in symptom severity following the initiation of treatment.
Initial Findings: Results from these trials were mixed, with some reports noted changes in mobility scores and others showing no significant difference when compared to a control group.

Long-Term Studies

Follow-up studies of up to 12 months in duration examined the long-term association between treatment and symptom change. These studies included patient-reported outcomes.

Patient Outcomes: Studies examined whether the combination was associated with patient outcomes, focusing on indicators like return to daily activity.
Mechanism of Action: Research also explored the possible processes involved in the substance’s observed action.

Application in Chronic Conditions

Studies evaluated the substance’s administration in combination with conventional therapies for chronic conditions.

Co-administration: Specific studies examined the substance’s review profile when co-administered with other treatments.
Interactions: Research included investigation into various interactions within specific patient groups, such as those with condition X.
Placebo Comparison: One study compared the result to placebo. This study used a single-blind, crossover design across 12 hospitals.

Key Studies & References

Long-Term Association of Ibunastizol with Patient-Reported Outcomes (12-Month Follow-up)

Frequently Asked Questions (FAQ)

Common questions about Ibunastizol (FAQ)

Q: Is Ibunastizol a painkiller or something else?

Ibunastizol is classified as a fixed-dose combination product. It contains two distinct active ingredients. One component, Ibuprofen, acts as an analgesic (painkiller) and antipyretic (fever reducer), while the other component, Pseudoephedrine, functions as a nasal decongestant. Official sources describe its use for addressing these symptoms simultaneously.

Q: Why do people use Ibunastizol?

According to the official product information, Ibunastizol is used to provide symptomatic relief during illnesses such as a cold or flu. Its general therapeutic purpose is to target common concurrent discomforts, including headache, minor body aches, fever, and the sinus pressure resulting from nasal congestion.

Q: Is it common to feel tired when using Ibunastizol?

Official regulatory documents classify certain central nervous system effects based on frequency. Side effects such as somnolence (sleepiness) are considered Common (potentially affecting up to 1 in 10 people) and fatigue is categorized as Uncommon. Therefore, feeling tired is a possibility reported in the official safety profile.

Q: Can Ibunastizol cause problems with sleep?

Yes, regulatory documentation indicates that the nervous system may be affected, which can include sleep issues. Trouble sleeping or difficulty falling asleep has been reported. This effect is often attributed to the stimulant properties of the Pseudoephedrine decongestant component.

Q: Are there any long-term side effects known for Ibunastizol?

Ibunastizol is explicitly labeled for short-term administration only, with specific time limits. Official documents emphasize that use beyond the short-term duration described on the label is associated with increased risks of serious adverse effects. These risks include potential cardiovascular issues and gastrointestinal complications, which are known safety concerns of the Ibuprofen component.

Q: Is it okay to take Ibunastizol with common cold medicine?

Official regulatory warnings advise against combining Ibunastizol with other medicines that contain Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or other sympathomimetic agents (decongestants). Since many common cold medicines contain one or both of these ingredients, taking them together may increase the risk of severe side effects.

Q: Are there food restrictions when using Ibunastizol?

The primary substance-related warning is regarding the use with alcohol (ethanol). Official sources state that combining Ibuprofen with alcohol significantly increases the risk of serious gastrointestinal adverse events. Regarding food intake, the medication may be taken with food or milk to help minimize potential stomach discomfort.

Q: Is Ibunastizol considered safe during pregnancy?

Official regulatory documents state that Ibunastizol is contraindicated during the third trimester of pregnancy (last 3 months). Use during the first and second trimesters, as well as during breastfeeding, is generally not recommended due to potential risks associated with the active components.

Q: Is Ibunastizol suitable for people with kidney problems?

Regulatory documents state that Ibunastizol is strictly contraindicated for patients with severe renal impairment (a serious form of kidney failure). Official guidance indicates caution may be necessary for patients with kidney conditions that are not classified as severe renal impairment.

Q: Can Ibunastizol be used by people with a history of heart issues?

The medication is absolutely contraindicated for patients with specific cardiovascular conditions, including severe heart failure, uncontrolled severe hypertension, or coronary heart disease. Due to the risk of cardiovascular events, official documents also prohibit its use around Coronary Artery Bypass Graft (CABG) surgery.

Q: Has Ibunastizol been studied for other conditions besides its main use?

Yes, official research overviews indicate that studies have examined the substance’s administration in combination with conventional therapies for certain chronic conditions. Research has also included investigations into its use within specific patient groups beyond its immediate indication for cold and flu symptoms.

Q: Is Ibunastizol addictive?

Official regulatory classification states that Ibunastizol is not a controlled drug under the Controlled Substances Act (CSA) in the United States. However, the Pseudoephedrine component is a sympathomimetic amine with stimulant properties that is subject to specific government regulations to help prevent misuse.

Q: Does Ibunastizol show up on drug tests?

The active ingredient Pseudoephedrine is structurally similar to amphetamines. Though the drug is not a controlled substance, official information suggests that consuming products containing Pseudoephedrine may potentially cause a positive result in certain preliminary drug screenings due to cross-reactivity with tests for amphetamines.

Q: Is there a maximum amount of time Ibunastizol can be used?

Yes, regulatory instructions specify limits for continuous administration. The medication should not be used for more than 3 days for fever or typically longer than 7 days for pain and nasal congestion unless specifically advised by a healthcare professional.

Q: What research is available on Ibunastizol for pediatric use?

Official safety information indicates that use is not recommended for pediatric patients. This is due to a lack of sufficient safety data establishing the risk-benefit profile for children under 12 years of age in regulatory documents.

Q: Are there any specific safety warnings for women taking Ibunastizol?

Safety warnings specific to women primarily relate to reproduction. These include the absolute contraindication during the third trimester of pregnancy and the non-recommendation during breastfeeding. Furthermore, the Ibuprofen component, an NSAID, is associated in some evidence with a reversible delay in ovulation.

Q: Can people with diabetes use Ibunastizol?

Official guidance indicates that caution may be necessary for patients with diabetes mellitus. The NSAID component can increase the risk of high blood potassium levels (hyperkalemia), and concurrent monitoring for such effects may be recommended by official labeling.

Q: Does the time of day matter when using Ibunastizol?

The Pseudoephedrine component in the product is known to be a stimulant. Regulatory documents list trouble sleeping as a possible side effect. The time of day the medication is taken, particularly near bedtime, may increase the likelihood of experiencing difficulties with sleep due to the stimulant component.

Q: How is Ibunastizol eliminated from the body?

Both active components are processed by the body’s established clearance pathways. The Ibuprofen component is extensively metabolized by the liver and primarily excreted via the kidneys. The Pseudoephedrine component is mostly eliminated unchanged in the urine.

Q: What are the known severe drug interactions with Ibunastizol?

Official regulatory documents identify combinations that are strictly contraindicated. This includes taking Ibunastizol with Monoamine Oxidase Inhibitors (MAOIs), which carries the risk of a hypertensive crisis, and with other NSAIDs, which significantly increases the risk of severe gastrointestinal bleeding.

Q: Is Ibunastizol a controlled substance?

No, official regulatory documents classify Ibunastizol as Not a controlled drug under the Controlled Substances Act (CSA). The Pseudoephedrine component is regulated but the final combined product is not classified as a controlled substance.

Q: What is the difference between Ibunastizol and its active ingredient name?

Ibunastizol is the brand or product name for a specific medicine. Its active ingredient name refers to the combination of the two components it contains: Ibuprofen and Pseudoephedrine Hydrochloride.

Q: Does Ibunastizol affect liver function?

Official safety information indicates that Ibunastizol may affect the liver. Elevated liver enzymes have been reported as a rare side effect. Caution is therefore advised in regulatory documentation for patients with any pre-existing hepatic impairment (liver problems).

Q: What happens if I use Ibunastizol for a long time?

The product is strictly labeled for short-term administration, typically for no more than 3 to 7 days. Using it for a longer duration than advised increases the known risks associated with the Ibuprofen component, including the risk of serious gastrointestinal and cardiovascular adverse events.

Q: What happens if I stop taking Ibunastizol suddenly?

Regulatory guidance specifies that this medication is for short-term use only. Discontinuation after prolonged or excessive use of the decongestant component may be associated with the return of nasal congestion, which is sometimes described in medical literature as rebound congestion.

Q: Is it normal to feel nauseous after starting Ibunastizol?

Yes, regulatory documentation indicates that nausea and abdominal discomfort are categorized as Common side effects. This means they are known to affect up to 1 in 10 people, according to the official safety profile.

Q: Does the evidence support long-term use of Ibunastizol?

The official research overview states that the evidence remains limited regarding the long-term association with symptom change for this medication. Consequently, the product is marketed and labeled strictly for short-term use.

How should Ibunastizol be stored and disposed of?

How to Store and Dispose of Ibunastizol

Official regulatory guidelines for Ibunastizol (Ibuprofen/Pseudoephedrine) define strict storage and disposal procedures to ensure product stability and safety.

Storage Requirement	Specification
Temperature	Store at controlled room temperature (20^circ to 25 C / 68^circ to 77 F). Do not freeze and avoid excessive heat.
Protection	Keep the medicine away from direct light and excessive moisture.
Container	Keep the product in its closed container and the original carton.
Child Safety	Mandatory instruction: Keep out of the reach of children.

For disposal, follow any specific instructions on the label. The preferred method is using a community drug take-back program. Medicines should not be flushed down the toilet or poured down a sink unless specifically authorized by the product's official labeling.

Ibunastizol